Strategic Target Adjustment Revamps Antibiotic Development
TXA-709 is a new type of antibiotic being developed by TAXIS Pharmaceuticals. The antibiotic specifically targets variants of the MRSA bacteria. TXA-709, a FtsZ-targeting benzamide prodrug, should be able to circumvent the problem of antibiotic resistance in certain bacterial infections by targeting previously neglected portions of these harmful microbes.
Rather than formulating a slightly different version of a previously effective antibiotic, TAXIS scientists are synthesizing new chemical entities with uniques mechanisms of action. This approach offers a distinct advantage when designing treatments to overcome multi-drug resistant bacteria. TXA-709 has yielded very promising results in pre-clinical trials. If approved, the drug will have the added benefit of being orally efficacious, which will make it easy to administer to patients.
For more videos, visit our partners at The Doctor's Channel.